According to Anjan Sen, Commercial Director and Lead for the South Asia Region at Organon, "India is an important market because of its growth potential, government commitment, and active role played by non-profit partners in the area of women's health."
Reproductive medicine, contraception, psychiatry, hormone replacement treatment, and anaesthesia are all areas of concentration for the US-based corporation having a presence in India.
Given India's huge and young population, the high rate of unwanted pregnancies and abortions highlights the need for high-quality contraception options. The industry has the potential to grow significantly, he continued, because of the dedication of government and non-profit partners to make contraceptive services available, as well as the network of public and private healthcare providers.
We have a presence in over 140 markets around the world. Our South, East, and South-East Asia cluster includes India. In India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives, we serve a population of 1.8 billion people. The subcontinent is a significant market for women's health because of its huge and young population, as well as fast changing demographic patterns. In an email to Pharmabiz, Sen stated, "We intend to invest in our women's health portfolio and examine the possibilities of working closely with local stakeholders to expand the consumption of our products."
Unintended pregnancies and infertility are both a problem in India. Factors such as the prevalence of various health issues among women, government measures to reduce population growth, and rising demand for contraceptives to prevent unwanted pregnancies are driving market expansion. The Indian government is constantly attempting to empower women through its programmes. More women will seek contraceptive options in the coming days, he said, as their levels of education and engagement in the formal workforce rise along with their awareness.
“We expect to double our presence in the next five years and provide access of our products to many more women throughout South Asia. In some of these markets, we are already involved with the government's family planning program, and we are optimistic that this will happen in India soon. Our pipeline of new products is also very relevant to our population’s healthcare needs. In addition, through our ongoing campaign ‘hereforherhealth.com,’ we will continue to listen to women to understand their healthcare needs and bring innovative solutions for these issues, he stated.
Organon has already announced four partnerships and acquisitions since becoming an independent firm in June of last year. The first acquisition was of Alydia Health, which is well known for its JADA postpartum bleeding treatment, which is currently available in the United States. Forendo Pharma, the second acquisition, includes two experimental treatments for endometriosis and PCOS. The third is a global licencing agreement with Daré Bioscience, which gives Organon the rights to market Xaciato, an FDA-approved bacterial vaginosis therapy. The fourth is a worldwide licence deal with ObsEva to develop and market Ebopiprant (OBE022), an investigational drug being tested as a first-in-class therapy for premature labour. In addition, Sen stated, "we are aiming to bring products from our worldwide portfolio to India."a
